Figma Shares Indicated To Open $105/$110
On Wednesday, TD Cowen adjusted its outlook on Geron Corporation (NASDAQ:GERN), reducing the price target from $10.00 to $5.00, while still holding a Buy rating on the stock. The decision followed the report of fourth-quarter sales for Rytelo, Geron’s flagship product, which, despite surpassing the expected range of $45-46 million with $47.5 million in sales, showed a concerning trend. According to the analyst, sales are flattening due to the drug’s early relegation to third-line (3L) therapy. The stock, currently trading at $1.62, has fallen significantly from its 52-week high of $5.34, though InvestingPro data indicates the company maintains a strong balance sheet with more cash than debt.
The analyst highlighted the importance of new patient starts from earlier lines of therapy as essential for the company’s growth moving forward into 2025. According to InvestingPro analysis, analysts anticipate substantial sales growth of over 300% for the current year. Geron’s strategy to counteract the flattening sales involves a strong emphasis on regional engagement through its field teams. These teams are tasked with ensuring that physicians are well-informed about the drug, aiming to optimize performance across all accounts.
Geron’s reliance on its field teams is part of a broader effort to maintain the drug’s market position and to prevent further relegation to later lines of therapy. The company’s proactive approach is geared towards increasing the adoption of Rytelo in earlier treatment stages, which could potentially lead to sustained sales growth.
The adjustment in price target by TD Cowen reflects the mixed outcome of Rytelo’s recent sales performance. While the sales figure for the fourth quarter was higher than anticipated, the growth trajectory is not as robust as previously expected due to the drug’s positioning in the treatment protocol.
Geron Corporation, which is focused on the development and commercialization of therapies for hematologic malignancies, will continue to navigate the competitive landscape. The company’s efforts to drive growth through strategic physician engagement will be a critical factor in its performance in the coming years. While the company’s current financial health score is rated as ’Fair’ by InvestingPro, with a comfortable current ratio of 2.89, investors should note that the stock appears undervalued based on InvestingPro’s Fair Value analysis. For deeper insights into Geron’s financial metrics and growth potential, including 13 additional ProTips and comprehensive valuation analysis, explore the full InvestingPro Research Report.
In other recent news, Geron Corporation reported its fourth-quarter 2024 earnings, falling short of analyst expectations with an earnings per share (EPS) of -$0.04, compared to a forecasted -$0.03. The company’s revenue for the quarter was $47.54 million, significantly below the anticipated $61.93 million. Despite a strong cash position of $502.9 million, the financial performance has raised investor concerns, leading to a notable decline in stock value. Geron anticipates operating expenses for 2025 to range between $270 million and $285 million, with expectations of reaching profitability without additional financing. Analysts from firms such as Stifel have highlighted challenges in increasing physician education and changing prescribing behaviors, impacting the uptake of Rytelo, a newly approved drug. The company remains optimistic about Rytelo’s potential, especially with anticipated EU approval in the first half of 2025. Recent management changes and strategic adjustments aim to address market penetration and improve commercial strategies. These developments underscore the company’s ongoing efforts to enhance its financial and operational performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.